Drug Profile
Research programme: cancer therapeutics - Onyx/UCSF
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Onyx Pharmaceuticals; University of California at San Francisco
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Haematological-malignancies in USA
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA
- 01 Oct 2013 Onyx Pharmaceuticals has been acquired by Amgen